Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 116,516 Shares

Aratana Therapeutics, Inc. (NASDAQ:PETX) major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of Aratana Therapeutics stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $6.53, for a total value of $760,849.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Friday, December 1st, Healthcare Master Fun Broadfin sold 890,516 shares of Aratana Therapeutics stock. The shares were sold at an average price of $5.70, for a total value of $5,075,941.20.

Aratana Therapeutics, Inc. (NASDAQ PETX) traded down $0.40 during trading hours on Friday, hitting $5.45. The stock had a trading volume of 1,693,865 shares, compared to its average volume of 414,827. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26. Aratana Therapeutics, Inc. has a 1 year low of $4.97 and a 1 year high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s quarterly revenue was up 1440.0% on a year-over-year basis. During the same period last year, the company earned ($0.38) earnings per share. research analysts expect that Aratana Therapeutics, Inc. will post -1.03 earnings per share for the current year.

A number of research analysts recently weighed in on PETX shares. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 18th. HC Wainwright initiated coverage on Aratana Therapeutics in a research report on Friday, November 17th. They set a “buy” rating and a $10.00 target price for the company. Jefferies Group set a $9.00 target price on Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 16th. ValuEngine downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Lake Street Capital cut their target price on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $8.75.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PETX. American International Group Inc. grew its stake in Aratana Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,354 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aratana Therapeutics by 13.9% in the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after purchasing an additional 235,208 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Aratana Therapeutics by 4.5% in the first quarter. Geode Capital Management LLC now owns 243,352 shares of the biopharmaceutical company’s stock valued at $1,289,000 after purchasing an additional 10,465 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Aratana Therapeutics by 85.7% in the first quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock valued at $680,000 after purchasing an additional 59,181 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in shares of Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 3,883 shares in the last quarter. 73.95% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 116,516 Shares” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/aratana-therapeutics-inc-petx-major-shareholder-healthcare-master-fun-broadfin-sells-116516-shares.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply